Highest-materiality recent filing
Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80
GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).
Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP
Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.
Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B
Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.
Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85
Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
Globus Medical Q2 net sales $745.3M (+18.4%); GAAP EPS $1.49, non-GAAP $0.86
Net sales $745.3M, up 18.4% YoY (17.6% constant currency); US Spine grew 5.7% as-reported.
Globus Medical CEO Scavilla resigns; Pfeil named CEO; preliminary Q2 sales $745.3M (+18% YoY)
Daniel Scavilla resigned as President and CEO effective July 18, 2025 to pursue another opportunity; no disagreement cited.
Globus Medical Q1 revenue down 1.4% to $598.1M; cuts non-GAAP EPS guidance to $3.00-$3.30
GAAP net income $75.5M; GAAP diluted EPS $0.54 vs ($0.05) a year ago.
Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash
Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.
Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact
Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M
All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.
Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B
Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.
Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance
Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
Globus Medical receives FDA warning letter for ExcelsiusGPS complaint procedures
FDA warning letter cites non-conformities in complaint handling, trending, risk reconciliation, and MDR reporting for the ExcelsiusGPS robotic system.
Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%
Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.
Globus Medical shareholders approve amendment to 2021 Equity Incentive Plan
Plan amendment approved with 244,115,224 votes for, 78,950,353 against; effective June 5, 2024.
Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance
Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.
Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance
Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.
On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings